A phase II safety and immunogenicity trial of live recombinant canarypox ALVAC-HIV vCP205 [HIV vaccine vCP205] with or without HIV-1 SF-2 RGP120 [HIV gp120 vaccine] in HIV-1 uninfected adult volunteers.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs HIV gp120 vaccine (Primary) ; HIV vaccine vCP205 (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 28 Sep 2008 Actual end date (Jan 2000) added as reported by CT.gov
- 28 Sep 2008 Actual start date (May 1997) added as reported by CT.gov
- 28 Sep 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov